Myeloma usually refers to multiple myeloma, a plasma-cell blood cancer arising in bone marrow and associated with monoclonal protein production, bone lesions, anemia, and renal complications.
A phase 2 trial in high-risk smoldering multiple myeloma found all 20 patients treated with cilta-cel became MRD-negative within two months and remained so after 15.3 months. No disease progression, death, dose-limiting toxicities, or high-grade side effects were observed.
Grail's NHS-Galleri trial of 142,000 participants failed to achieve statistically significant reduction in late-stage cancer diagnoses, though secondary endpoints showed four-fold improvement in overall cancer detection rate. Stock fell 48% following the announcement.
For the first time, 70% of cancer patients in the U.S. survive five years or more after diagnosis, according to the American Cancer Society's 2026 report. Advances in immunotherapy, CAR T-cell therapy, and screening technologies have driven significant improvements, particularly for lung cancer and myeloma. The definition of successful cancer care is evolving beyond survival to focus on quality of life and durable remissions.
A new report from the American Cancer Society shows 70% of cancer patients now survive five years or more, marking the first time this milestone has been reached. Improvements are attributed to advances in immunotherapy, CAR T-cell therapy, and expanded screening programs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600151 |
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07532473 |
REal World MAIA UK OutcomEs |
NOT_YET_RECRUITING | |
| NCT07390071 |
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy |
RECRUITING | NA |
| NCT07297160 |
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07206810 |
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients |
COMPLETED | |
| NCT07202091 |
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) |
RECRUITING | PHASE2/PHASE3 |
| NCT07202078 |
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) |
RECRUITING | PHASE2/PHASE3 |
| NCT07202065 |
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) |
RECRUITING | PHASE2/PHASE3 |
| NCT07202052 |
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) |
RECRUITING | PHASE2/PHASE3 |
| NCT07106671 |
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma |
RECRUITING | PHASE2 |
